- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04299048
Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.
A PHASE 1B, 12-WEEK, OPEN-LABEL STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS FOLLOWING REPEATED SUBCUTANEOUS ADMINISTRATIONS OF PF-06946860 IN PATIENTS WITH CANCER AND CACHEXIA
Study Overview
Status
Intervention / Treatment
Detailed Description
This 12-week open-label study will explore how PF-06946860 is tolerated, the effects of the study drug, the best dose for treatment and how participants with non-small cell lung, pancreatic or colorectal cancer and cachexia feel after receiving repeated subcutaneous dosing. During the 12-week treatment period, study drug will be administered subcutaneously every 3 weeks for a total of 5 doses. There is a 12-week follow-up period following the last dose of study drug. Additional assessments include:
- body weight measurements
- blood pressure and heart rate measurements
- Lumbar Skeletal Muscle Index (LSMI) by CT scan
Blood samples:
- to evaluate safety,
- to measure the amount of the study drug in the blood,
- to evaluate if the study drug causes an immune response,
- to examine the effects of the study drug on levels of a specific cytokine,
- and for exploratory samples for bio banking.
- Measure the impact of the study drug on appetite, nausea, vomiting, fatigue, physical function, and health-related quality of life with questionnaires.
- Measure the impact of study drug on physical activity using wearable digital sensors.
- To evaluate the effect of study drug on ability to complete anti-tumor treatment and survival in participants with cancer and cachexia.
- To evaluate tumor size.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Beverly Hills, California, United States, 90211
- Beverly Hills Cancer Center
-
-
Colorado
-
Grand Junction, Colorado, United States, 81501
- SCL Health Cancer Centers of Colorado - St. Mary's Hospital and Regional Medical Center
-
Wheat Ridge, Colorado, United States, 80033
- Lutheran Medical Center
-
-
Florida
-
Tallahassee, Florida, United States, 32308
- Tallahassee Memorial Healthcare Cancer Center
-
-
Indiana
-
Fort Wayne, Indiana, United States, 46804
- Fort Wayne Medical Oncology and Hematology, Inc.
-
-
Maine
-
Scarborough, Maine, United States, 04074
- New England Cancer Specialists
-
-
Maryland
-
Bethesda, Maryland, United States, 20817
- American Oncology Partners of Maryland, PA
-
Germantown, Maryland, United States, 20874
- American Oncology Partners of Maryland, PA
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke Cancer Center
-
-
Washington
-
Seattle, Washington, United States, 98108
- VA Puget Sound Health Care System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Documented histologic or cytologic diagnosis of advanced metastatic NSCLC, advanced/unresectable pancreatic cancer, or metastatic colorectal cancer.
- Cachexia, defined by BMI <20 kg/m2 with involuntary weight loss of >2% within 6 months prior to screening or Involuntary weight loss of >5% within 6 months prior to screening irrespective of BMI or If medical record documentation is unavailable, patient's report will suffice to estimate involuntary body weight loss.;
Will receive the following for non-small cell lung cancer:
- a platinum + pemetrexed ± pembrolizumab or
- a platinum + nab paclitaxel or paclitaxel ± pembrolizumab or
- pembrolizumab alone
Will receive the following for pancreatic cancer:
- FOLFIRINOX or
- Nab-Paclitaxel + Gemcitabine
- Gemcitabine
Will receive the following for colorectal cancer:
- FOLFOX +/- Biologic (Bevacizumab or Cetuximab/Panitumumab) or
- FOLFIRI +/- Biologic (Bevacizumab or Cetuximab/Panitumumab) or
- FOLFOXIRI +/- Biologic (Bevacizumab or Cetuximab/Panitumumab) or
- Pembrolizumab for MSI-H • Will be entering the study at the first or second cycle of their current course of anti-cancer treatment/ therapy.
- Adequate renal and liver function.
- Signed informed consent.
Exclusion Criteria:
- All other forms of cancers not specified above unless currently considered cured (>5 years without evidence of recurrence).
- Planned radiation therapy as part of the primary anti-tumor therapy regimen. However, localized radiation therapy for symptomatic relief is permitted
- Cachexia caused by other reasons: Severe COPD requiring use of home O2, heart failure or AIDS.
- known symptomatic brain metastases requiring steroids.
- Active hepatitis B or C virus.
- Confirmed positive HIV test.
- Current active reversible causes of decreased food intake.
- Receiving tube feedings or parenteral nutrition at Screening.
- Elevated blood pressure that cannot be controlled by medications.
- Women who are pregnant or breast-feeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PF-06946860
subcutaneous injection
|
subcutaneous injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Time Frame: From Day 1 up to Week 24
|
An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
A serious adverse event (SAE) was defined as an AE: 1. resulting in death, 2. was life-threatening, 3. required inpatient hospitalization or prolongation of existing hospitalization, 4. resulted in persistent disability, 5. was a congenital anomaly/birth defect, or considered to be an important medical event.
An AE was considered an TEAE if the event started during the effective duration of treatment.
All events that started on or after the first dosing day and time/start time, if collected, but before the last dose plus the lag time were flagged as TEAEs.
|
From Day 1 up to Week 24
|
Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)
Time Frame: From Day 1 up to Week 24
|
Participants with laboratory test abnormalities (without regard to baseline abnormality) that met pre-specified criteria included Hemoglobin< 0.8x lower limit of normal (LLN); Hematocrit< 0.8x LLN; Erythrocytes (Ery.)<
0.8x LLN; Ery.
Mean Corpuscular Volume< 0.9x LLN; Leukocytes< 0.6x LLN; Lymphocytes< 0.8x LLN; Bilirubin> 1.5x upper limit of normal (ULN); Aspartate Aminotransferase> 3.0x ULN; Alkaline Phosphatase> 3.0x ULN; Protein< 0.8x LLN; Sodium< 0.95x LLN; Chloride< 0.9x LLN; Calcium< 0.9x LLN; Bicarbonate< 0.9x LLN; Glucose> 1.5x ULN; C Reactive Protein> 1.1x ULN; for urinalysis, Urine Glucose ≥1, Ketones ≥1, Urine Protein ≥1, Urine Hemoglobin ≥1, Urobilinogen ≥1, Nitrite ≥1, and Leukocyte ≥1 Esterase ≥1; Hyaline Casts >1/LPF.
|
From Day 1 up to Week 24
|
Number of Participants With Post-Baseline Vital Signs Abnormalities
Time Frame: From Day 1 up to Week 24
|
Vital signs (pulse rate, systolic and diastolic blood pressure) were obtained with participant in the supine position.
The pre-specified categorical analysis criteria in vital signs, were supine systolic blood pressure (SBP) <90 millimeters of mercury (mmHg), supine SBP increase/decrease from baseline ≥30 mmHg; supine diastolic blood pressure (DBP) <50 mmHg, supine DBP increase/decrease from baseline ≥20 mmHg; supine pulse rate <40 beats per minute (bpm) or >120 bpm.
|
From Day 1 up to Week 24
|
Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities
Time Frame: From Day 1 up to Week 24
|
ECG data (PR interval, QRS interval, QT interval, and QTcF) were obtained with participant in the supine position.
The pre-specified categorical analysis criteria in ECG, were PR interval: value ≥300 milliseconds (msec), percentage change ≥25/50%; QRS interval: value ≥140 msec, percentage change ≥50%; QT interval: value ≥500 msec; QTcF interval: 470< value ≤480 msec, 480< value ≤500 msec, value >500 msec, and 30< change ≤60 msec, change >60 msec.
|
From Day 1 up to Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum Unbound Trough Concentrations (Ctrough) of PF-06946860
Time Frame: Pre-dose at Weeks 3, 6, 9 and 12, and at Week 15
|
Ctrough was defined as the samples measured pre-dose at Weeks 3, 6, 9 and 12, and at Week 15.
Serum unbound Ctrough was summarized by time and treatment group.
|
Pre-dose at Weeks 3, 6, 9 and 12, and at Week 15
|
Serum Total Ctrough of PF-06946860
Time Frame: Pre-dose at Weeks 3, 6, 9 and 12, and at Week 15
|
Ctrough was defined as the samples measured pre-dose at Weeks 3, 6, 9 and 12, and at Week 15.
Serum total Ctrough was summarized by time and treatment group.
|
Pre-dose at Weeks 3, 6, 9 and 12, and at Week 15
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Pfizer CT.gov Call Center, Pfizer
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Metabolic Diseases
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Endocrine System Diseases
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Endocrine Gland Neoplasms
- Nutrition Disorders
- Body Weight
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Body Weight Changes
- Lung Neoplasms
- Pancreatic Diseases
- Weight Loss
- Thinness
- Carcinoma, Non-Small-Cell Lung
- Colorectal Neoplasms
- Pancreatic Neoplasms
- Wasting Syndrome
- Cachexia
Other Study ID Numbers
- C3651009
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Cancer
-
University of California, San FranciscoCompletedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRectal Cancer | Colon Cancer | Cancer Survivor | Colorectal Adenocarcinoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterRecruitingColorectal Adenocarcinoma | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedCancer Survivor | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal Cancer AJCC v8 | Stage IIB Colorectal... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...United States Department of DefenseActive, not recruitingColorectal Adenoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage 0 Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal... and other conditionsUnited States
-
City of Hope Medical CenterRecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Neoplasms Malignant | Colorectal Cancer Stage IUnited States, Japan, Italy, Spain
-
University of Roma La SapienzaCompletedColorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Cancer Stage 0 | Colorectal Cancer Stage IItaly
-
University of Southern CaliforniaNational Cancer Institute (NCI); AmgenTerminatedStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | RAS Wild Type | Stage III Colorectal Cancer AJCC v7 | Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer...United States
Clinical Trials on PF-06946860
-
PfizerCompletedAnorexia | Breast Cancer | Fatigue | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Cachexia | Non-small Cell Lung Cancer | Loss of AppetiteUnited States, Canada
-
PfizerCompleted
-
PfizerCompleted
-
PfizerThrombolysis In Myocardial Infarction (TIMI)RecruitingHeart FailureUnited States, Canada, China, Australia, Spain, Japan, Czechia, Hungary, United Kingdom, Poland, Germany
-
PfizerCompleted
-
University of FloridaCompletedGastrointestinal Symptoms | Stool Frequency | Gastrointestinal Transit TimeUnited States
-
PfizerCompleted
-
PfizerCompletedSchizophreniaUnited States
-
PfizerCompleted